table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 all comersCOVID-19 mild to moderateCOVID-19 severe or critically
COVID 19 hospitalizedCOVID 19 all comersCOVID-19 mild to moderateCOVID-19 severe or critically
Immunosuppressants drugs
abatacept ACTIV-1 abatacept
adalimumab Fakharian
anakinra SAVE-MORE CORIMUNO-ANA-1 Kooistra Ana-COVID ...
anti-interleukin-6
Levilimab V.Lomakin ...
sarilumab CORIMUNO-SARI-1 ... sarilumab Sanofi phase 3 US ARI-RAF ... REMAP-CAP sarilumab sarilumab Sanofi phase 3 outside US
sarilumab high dose (400mg) sarilumab phase 2 high dose Lescure ...
sarilumab low dose (200mg) sarimulab phase 2 low dose Lescure ...
tocilizumab EMPACTA RECOVERY NCT04479358 ... NCT04434717 ... Tsai Soin AS ... RCT-TCZ-COVID-19 HNF Hospital Tocilizumab multidisciplinary team NCT04412772 ... Declercq J ... Colaneri SAM-COVID-19 NCT04577534 ... Rutgers EU-CTR2020-001375-32 ... Dongsheng Wang Martinez-Sanz EU-CTR2020-001748-24 ... TOCOVID BACC Bay Tocilizumab Trial Capra Rojas-Marte Hamed MARIPOSA Pereira Karampitsakos Sarhan Somers CORIMUNO-TOCI-ICU ... Sarhan Biran CORIMUNO-TOCI-1 ... REMAP-CAP ... NCT04377750 ... Rashad Rosas ... Veiga Talaschian TOCI-RAF Study Group ... Mathilde Karakike ... Andrew COVACTA ... Belhassen-Garc??a
canakinumab Sheng ... CAN-COVID
cenicriviroc ACTIV-1 cenicriviroc
infliximab ACTIV-1 infliximab
itolizumab Kumar
janus kinase (JAK) inhibitor
baricitinib COV-BARRIER ACTT-2 ... RECOVERY Cantini Rodriguez-Garcia Tziolos COV-BARRIER ...
ruxolitinib Cao DEVENT
TD-0903
TD-0903 10mg Singh ...
TD-0903 1mg Singh ...
TD-0903 3mg Singh ...
tofacitinib STOP-COVID ... Murugesan
lenzilumab LIVE-AIR ...
tacrolimus TACROVID
thalidomide Amra

0 studies excluded by filtering options 2

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons